Immunogenicity and Safety of a 13-valent pneumococcal conjugate vaccine in paediatric oncology patients

Trial Profile

Immunogenicity and Safety of a 13-valent pneumococcal conjugate vaccine in paediatric oncology patients

Completed
Phase of Trial: Phase II/III

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Pneumococcal infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jul 2017 Status changed from recruiting to completed, according to the results published in the Cancer.
    • 19 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top